[Gastrointestinal stromal tumors. An update].
Gastrointestinal stromal tumors (GIS) are a heterogeneous group of tumors that express CD 117 molecule in their sur face. They may behave as benign tumors or be highly aggressive. A better survival of patients with these tumors has been achieved using the new molecular therapies such as imatinib mesylate, sunitinib and others. This review analyzes the prognostic factors of these tumors, their clinical features and the criteria for malignant behavior. The value of therapeutic alternatives such as radiotherapy chemotherapy and the new molecular therapies are also discussed.
Bórquez Ma
Pablo
P
Instituto Nacional del Cancer. tellomora@yahoo.es
Neveu C
Rodrigo
R
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D046152:Gastrointestinal Stromal Tumors / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles; D000077210:Sunitinib
D000970:Antineoplastic Agents; D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit; D000077210:Sunitinib